Literature DB >> 33779754

Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy.

Fernando Caravaca-Fontán1,2, Montserrat Díaz-Encarnación3, Virginia Cabello4, Gema Ariceta5, Luis F Quintana6,7, Helena Marco8, Xoana Barros9, Natalia Ramos10, Nuria Rodríguez-Mendiola11, Sonia Cruz12, Gema Fernández-Juárez13, Adela Rodríguez14, Ana Pérez de José15, Cristina Rabasco16, Raquel Rodado17, Loreto Fernández18, Vanessa Pérez Gómez19, Ana Ávila20, Luis Bravo21, Natalia Espinosa22, Natalia Allende23, Maria Dolores Sanchez de la Nieta24, Eva Rodríguez25, Teresa Olea26, Marta Melgosa27, Ana Huerta28, Rosa Miquel29, Carmen Mon30, Gloria Fraga31, Alberto de Lorenzo32, Juliana Draibe33, Marta Cano-Megías34, Fayna González35, Amir Shabaka36, Maria Esperanza López-Rubio37, María Ángeles Fenollosa38, Luis Martín-Penagos39, Iara Da Silva3, Juana Alonso Titos40, Santiago Rodríguez de Córdoba41,42, Elena Goicoechea de Jorge1,43, Manuel Praga1,2.   

Abstract

INTRODUCTION: The association between a change in proteinuria over time and its impact on kidney prognosis has not been analysed in complement component 3 (C3) glomerulopathy. This study aims to investigate the association between the longitudinal change in proteinuria and the risk of kidney failure.
METHODS: This was a retrospective, multicentre observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. A joint modelling of linear mixed-effects models was applied to assess the underlying trajectory of a repeatedly measured proteinuria, and a Cox model to evaluate the association of this trajectory with the risk of kidney failure.
RESULTS: The study group consisted of 85 patients, 70 C3 glomerulonephritis and 15 dense deposit disease, with a median age of 26 years (range 13-41). During a median follow-up of 42 months, 25 patients reached kidney failure. The longitudinal change in proteinuria showed a strong association with the risk of this outcome, with a doubling of proteinuria levels resulting in a 2.5-fold increase of the risk. A second model showed that a ≥50% proteinuria reduction over time was significantly associated with a lower risk of kidney failure (hazard ratio 0.79; 95% confidence interval 0.56-0.97; P < 0.001). This association was also found when the ≥50% proteinuria reduction was observed within the first 6 and 12 months of follow-up.
CONCLUSIONS: The longitudinal change in proteinuria is strongly associated with the risk of kidney failure. The change in proteinuria over time can provide clinicians a dynamic prediction of kidney outcomes.
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA.

Entities:  

Keywords:  C3 glomerulopathy; joint models; kidney failure; proteinuria

Mesh:

Substances:

Year:  2022        PMID: 33779754     DOI: 10.1093/ndt/gfab075

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   7.186


  4 in total

1.  Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis.

Authors:  Hannah J Lomax-Browne; Nicholas R Medjeral-Thomas; Sean J Barbour; Jack Gisby; Heedeok Han; Andrew S Bomback; Fernando C Fervenza; Thomas H Cairns; Richard Szydlo; Sven-Jean Tan; Stephen D Marks; Aoife M Waters; Gerald B Appel; Vivette D D'Agati; Sanjeev Sethi; Cynthia C Nast; Ingeborg Bajema; Charles E Alpers; Agnes B Fogo; Christoph Licht; Fadi Fakhouri; Daniel C Cattran; James E Peters; H Terence Cook; Matthew C Pickering
Journal:  Clin J Am Soc Nephrol       Date:  2022-07       Impact factor: 10.614

2.  Prognostication for C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis.

Authors:  Fernando Caravaca-Fontán; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2022-07       Impact factor: 10.614

3.  Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy.

Authors:  Fernando Caravaca-Fontán; Marta Rivero; Teresa Cavero; Montserrat Díaz-Encarnación; Virginia Cabello; Gema Ariceta; Luis F Quintana; Helena Marco; Xoana Barros; Natalia Ramos; Nuria Rodríguez-Mendiola; Sonia Cruz; Gema Fernández-Juárez; Adela Rodríguez; Ana Pérez de José; Cristina Rabasco; Raquel Rodado; Loreto Fernández; Vanessa Pérez-Gómez; Ana Ávila; Luis Bravo; Natalia Espinosa; Natalia Allende; Maria Dolores Sanchez de la Nieta; Eva Rodríguez; Teresa Olea; Marta Melgosa; Ana Huerta; Rosa Miquel; Carmen Mon; Gloria Fraga; Alberto de Lorenzo; Juliana Draibe; Fayna González; Amir Shabaka; Maria Esperanza López-Rubio; María Ángeles Fenollosa; Luis Martín-Penagos; Iara Da Silva; Juana Alonso Titos; Santiago Rodríguez de Córdoba; Elena Goicoechea de Jorge; Manuel Praga
Journal:  Clin Kidney J       Date:  2022-04-28

4.  Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.

Authors:  Andrew S Bomback; David Kavanagh; Marina Vivarelli; Matthias Meier; Yaqin Wang; Nicholas J A Webb; Angelo J Trapani; Richard J H Smith
Journal:  Kidney Int Rep       Date:  2022-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.